Abstract

The Section is the statistical and data management component of the Center for Cancer Research (CCR). The Section provides statistical leadership and data management consultation for major activities of the Center, and is involved in the design, conduct, monitoring, and statistical analyses of intramural and national multicenter clinical trials of experimental treatments for cancer, and intramural clinical trials for treatment of AIDS. The section provides a broad range of data analysis and consultation services to laboratories performing basic scientific research into the origin and growth mechanisms of cancer and AIDS. Other major collaborative efforts include studies to identify important prognostic and treatment selection factors, evaluate diagnostic procedures, develop improved staging systems, and assist investigators in the design, execution, and analyses of major in vitro drug testing studies. The Section develops and implements new statistical designs and biometric methods related to the development and evaluation of new cancer and AIDS treatments. The Section maintains a unified system for tracking basic information on all patients registered on CCR treatment protocols. Approximately 20% of the Section's activities are HIV-AIDS related.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Support Services Intramural Research (ZID)
Project #
1ZIDSC007202-29
Application #
8554188
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
29
Fiscal Year
2012
Total Cost
$781,212
Indirect Cost

  Institution

Name
National Cancer Institute Division of Clinical Sciences
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Terabe, Masaki; Robertson, Faith C; Clark, Katharine et al. (2017) Blockade of only TGF-? 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy. Oncoimmunology 6:e1308616
Dosani, Talib; Mailankody, Sham; Korde, Neha et al. (2017) Host-related immunodeficiency in the development of multiple myeloma. Leuk Lymphoma :1-6
Assadipour, Yasmine; Sadowski, Samira M; Alimchandani, Meghna et al. (2017) SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma. Surgery 161:230-239
Sui, Yongjun; Lee, Eun Mi; Wang, Yichuan et al. (2016) Early SIV Dissemination After Intrarectal SIVmac251 Challenge Was Associated With Proliferating Virus-Susceptible Cells in the Colorectum. J Acquir Immune Defic Syndr 71:353-8
Feingold, Paul L; Quadri, Humair S; Steinberg, Seth M et al. (2016) Thoracic Surgery in Chronic Granulomatous Disease: a 25-Year Single-Institution Experience. J Clin Immunol 36:677-83
Dine, Jennifer L; O'Sullivan, Ciara C; Voeller, Donna et al. (2016) The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Res Treat 155:235-51
Tuero, Iskra; Venzon, David; Robert-Guroff, Marjorie (2016) Mucosal and Systemic ??+ T Cells Associated with Control of Simian Immunodeficiency Virus Infection. J Immunol 197:4686-4695
Gharwan, Helen; Lai, Catherine; Grant, Cliona et al. (2016) Female fertility following dose-adjusted EPOCH-R chemotherapy in primary mediastinal B-cell lymphomas. Leuk Lymphoma 57:1616-24
Assadipour, Yasmine; Azoury, Saïd C; Schaub, Nicholas N et al. (2016) Significance of preoperative radiographic pancreatic density in predicting pancreatic fistula after surgery for pancreatic neuroendocrine tumors. Am J Surg 212:40-6
Merchant, Melinda S; Bernstein, Donna; Amoako, Martha et al. (2016) Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas. Clin Cancer Res 22:3182-91

Showing the most recent 10 out of 148 publications